Phase
Condition
Atrial Fibrillation
Chest Pain
Dysrhythmia
Treatment
AdKCNH2-G628S
Clinical Study ID
Ages > 18 All Genders
Study Summary
Eligibility Criteria
Inclusion
Inclusion:
Elective valve surgery (alone or with coronary artery bypass grafting surgery) and one of the risk factors listed below, or elective coronary artery bypass grafting surgery with two of the risk factors listed below.
Risk factors:
age greater than 70,
increased left atrial size (> 4 cm left atrial diameter or LA volume index > 35 on echocardiogram).
obesity (body mass index > 30)
history of:
paroxysmal AF
hypertension
chronic pulmonary disease
diabetes mellitus
clinical heart failure
rheumatic heart disease
Exclusion:
persistent or permanent AF
QTc > 475 on pre-op ECG or any time in last year (unless due to QT prolonging drug that was stopped > 5 half-lives before surgery with verification of QT normalization after discontinuing drug)
QTc prolonging drug use (unless stopped > 5 half-lives prior to surgery)
Any antiarrhythmic drug use in last year (inclusive of Vaughan Williams class I and III drugs, not including β-blocker or calcium channel blocker drugs)
Any history of inherited arrhythmia syndrome
Any prior or current sustained ventricular arrhythmias
Any prior or current clinically significant bradyarrhythmias unless already treated with pacemaker and ventricular pacing <20% (to reliable measure QT interval during the study)
Any prior gene therapy
Left ventricular ejection fraction (LVEF) < 35%
Prior open chest surgery
History of or current malignancy, unless documented to be cured
History of or current chemotherapy, radiotherapy, or other immunosuppressive therapy within the past 30 days. Corticosteroid treatment may be permitted at the discretion of the Primary Investigator
History of infection with human immunodeficiency virus (HIV), hepatitis A, B, or C, or tuberculosis
Immunizations of any kind in the month prior to surgery
Underlying defect in immune function or history of multiple or severe life-threatening infections
Significant liver disease (active hepatitis, AST or ALT greater than twice the upper limit of normal, prior or current liver failure with Pugh-Child category A-C disease)
Significant renal disease (GFR less than 30)
Current pregnancy
Childbearing potential unless participant agrees to prevent pregnancy prior to and for at least 3 months after virus delivery 10
Any condition that limits life to < 12 months other than the condition to be treated with the planned surgery
Participation in any other clinical trial within 30 days of surgery
Incarcerated persons
Individuals under the age of 18 years
Unwillingness to undergo the study interventions and follow-up as outlined in the schedule of events
Ongoing medical or other condition that is deemed by the Principal Investigator to interfere with the conduct or assessments of the study
Lack of capacity to provide participant's own informed consent.
Study Design
Study Description
Connect with a study center
UMass Memorial Hospital
Worcester, Massachusetts 01655
United StatesSite Not Available
Not the study for you?
Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.